PharmaCyte (PMCB) investors cap beneficial ownership at 4.99% with warrant blockers

Rhea-AI Filing Summary

PharmaCyte Biotech, Inc. investors update their ownership report. As of the close of business on December 31, 2025, Mitchell P. Kopin and Intracoastal Capital LLC each report beneficial ownership of 532,254 shares of common stock, or about 4.99% of the class. Daniel B. Asher reports beneficial ownership of 531,086 shares, also about 4.99%.

Their positions are mainly through warrants and preferred stock held by Intracoastal. Multiple warrants and Series H Convertible Preferred Stock include 4.99% blocker provisions, which limit conversions or exercises that would push their beneficial ownership above that threshold. The percentages are calculated using 10,134,160 shares outstanding as of December 16, 2025 plus specified warrant shares.

The reporting persons certify the securities are not held for the purpose of changing or influencing control of PharmaCyte, and the filing reflects that they each own 5 percent or less of the common stock class.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 7)

PharmaCyte Biotech, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

71715X203

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 71715X203

1

Names of Reporting Persons

Mitchell P. Kopin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 532,254.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 532,254.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

532,254.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 71715X203

1

Names of Reporting Persons

Daniel B. Asher

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 22,227.00
6	Shared Voting Power 508,859.00
7	Sole Dispositive Power 22,227.00
8	Shared Dispositive Power 508,859.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

531,086.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 71715X203

1

Names of Reporting Persons

Intracoastal Capital LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 532,254.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 532,254.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

532,254.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PharmaCyte Biotech, Inc.
(b)	Address of issuer's principal executive offices: 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
(c)	Citizenship: Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 71715X203
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of the close of business on December 31, 2025, each of Intracoastal and Mr. Kopin may have been deemed to have beneficial ownership of 532,254 shares of Common Stock, which consisted of (i) 500,000 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 1") and (ii) 32,254 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal ("Intracoastal Warrant 2"), and all such shares of Common Stock represented beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 10,134,160 shares of Common Stock outstanding as of December 16, 2025, as reported by the Issuer, plus (2) 500,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (2) 32,254 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes (I) 96,893 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (II) 9,720,474 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal ("Intracoastal Warrant 3") because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (III) 2,104,478 shares of Common Stock issuable upon exercise of a fourth warrant held by Intracoastal ("Intracoastal Warrant 4") because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (IV) 608,553 shares of Common Stock issuable upon exercise of a fifth warrant held by Intracoastal ("Intracoastal Warrant 5") because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock and (V) 1,871,515 shares of Common Stock issuable upon conversion of Series H Convertible Preferred Stock (the "Preferred Stock") held by Intracoastal because the terms of the Preferred Stock contain a blocker provision under which the holder thereof does not have the right to convert the Preferred Stock to the extent (but only to the extent) that such conversion would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of Intracoastal and Mr. Kopin may have been deemed to have beneficial ownership of 14,934,167 shares of Common Stock. As of the close of business on December 31, 2025, Mr. Asher may have been deemed to have beneficial ownership of 531,086 shares of Common Stock, which consisted of (i) 22,227 shares of Common Stock held by Mr. Asher, (ii) 500,000 shares of Common Stock issuable upon exercise Intracoastal Warrant 1 and (iii) 8,859 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock represented beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 10,134,160 shares of Common Stock outstanding as of December 16, 2025, as reported by the Issuer, plus (2) 500,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (3) 8,859 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes (I) 120,288 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (II) 9,720,474 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (III) 2,104,478 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4 because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (IV) 608,553 shares of Common Stock issuable upon exercise of Intracoastal Warrant 5 because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock and (V) 1,871,515 shares of Common Stock issuable upon conversion of the Preferred Stock held by Intracoastal because the terms of the Preferred Stock contain a blocker provision under which the holder thereof does not have the right to convert the Preferred Stock to the extent (but only to the extent) that such conversion would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, Mr. Asher may have been deemed to have beneficial ownership of 14,956,394 shares of Common Stock.
(b)	Percent of class: 4.99 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0 shares of Common Stock with respect to Mr. Kopin and Intracoastal. 22,227 shares of Common Stock with respect to Mr. Asher.
	(ii) Shared power to vote or to direct the vote: 532,254 shares of Common Stock with respect to Mr. Kopin and Intracoastal. 508,859 shares of Common Stock with respect to Mr. Asher.
	(iii) Sole power to dispose or to direct the disposition of: 0 shares of Common Stock with respect to Mr. Kopin and Intracoastal. 22,227 shares of Common Stock with respect to Mr. Asher.
	(iv) Shared power to dispose or to direct the disposition of: 532,254 shares of Common Stock with respect to Mr. Kopin and Intracoastal. 508,859 shares of Common Stock with respect to Mr. Asher.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mitchell P. Kopin

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin
Date:	02/13/2026

Daniel B. Asher

Signature:	/s/ Daniel B. Asher
Name/Title:	Daniel B. Asher
Date:	02/13/2026

Intracoastal Capital LLC

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin, Manager
Date:	02/13/2026

FAQ

What ownership stake in PMCB does Intracoastal Capital report on this Schedule 13G/A?

Intracoastal Capital reports beneficial ownership of 532,254 shares of PharmaCyte Biotech common stock, representing about 4.99% of the class. This figure is based on 10,134,160 shares outstanding as of December 16, 2025, plus specified warrant shares.

How many PharmaCyte (PMCB) shares does Mitchell P. Kopin beneficially own?

Mitchell P. Kopin may be deemed to beneficially own 532,254 shares of PharmaCyte common stock, or approximately 4.99% of the class. This amount matches Intracoastal’s position, reflecting warrants held by Intracoastal and calculated using the issuer’s reported outstanding share count.

What is Daniel B. Asher’s reported ownership percentage in PharmaCyte (PMCB)?

Daniel B. Asher reports beneficial ownership of 531,086 PharmaCyte common shares, representing about 4.99% of the class. His stake includes 22,227 shares held directly and additional shares issuable upon exercise of Intracoastal warrants, subject to blocker provisions limiting ownership above 4.99%.

What are the 4.99% blocker provisions mentioned in the PharmaCyte (PMCB) filing?

Several Intracoastal warrants and the Series H Convertible Preferred Stock contain provisions preventing exercises or conversions that would result in beneficial ownership above 4.99% of PharmaCyte’s common stock. These blockers limit how many underlying shares are currently counted as beneficially owned.

How is the ownership percentage in this PharmaCyte (PMCB) Schedule 13G/A calculated?

The reported 4.99% ownership percentages are calculated using 10,134,160 PharmaCyte common shares outstanding as of December 16, 2025, plus specific shares issuable upon exercise of certain Intracoastal warrants. Additional warrant and preferred shares are excluded due to 4.99% blocker provisions.

Do the PharmaCyte (PMCB) reporting persons seek to influence control of the company?

The reporting persons certify that the securities were not acquired and are not held to change or influence control of PharmaCyte Biotech. They also state the holdings are not part of any transaction intended to have that purpose or effect, aside from limited nomination-related activities.